Core Insights - CytoMed Therapeutics Limited has published a preclinical study indicating the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML) [1][2] - The study was conducted in collaboration with The University of Texas, MD Anderson Cancer Center, under a research agreement established in May 2023 [1] - The findings support further clinical studies of allogeneic donor-derived γδ T cells for AML and other cancers, with plans to advance their next γδ T cell-based product into clinical trials [2] Company Overview - CytoMed, incorporated in 2018, is a clinical stage biopharmaceutical company focused on developing novel donor-derived cell-based immunotherapies for various cancers [3] - The company utilizes proprietary technologies, including gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, inspired by the success of CAR-T therapies in hematological malignancies [3] - CytoMed aims to provide innovative immunotherapy options for patients with limited treatment alternatives, particularly in Southeast Asia [3]

Core Viewpoint - The healthcare sector is experiencing significant stock price increases, with some stocks more than doubling in value since the end of July, indicating potential for further gains despite recent surges [1][2]. Group 1: Precigen - Precigen's shares increased by 155% from the end of July to September 5, following FDA approval for its first treatment, Papzimeos, which is aimed at recurrent respiratory papillomatosis (RRP) [4][5]. - Papzimeos is the first and only FDA-approved treatment for approximately 27,000 patients with RRP, with a notable response rate in clinical trials where 18 out of 35 patients avoided surgery for at least 12 months post-treatment [5][6]. - Analysts, including Swayampakula Ramakanth from HC Wainwright, have set a price target of $8.50 for Precigen, suggesting a potential 95% increase in the next year [6]. Group 2: Mineralys Therapeutics - Mineralys Therapeutics saw a 146% rise in stock price from the end of July to September 5, driven by a successful funding round for the development of its lead candidate, lorundrostat [7][8]. - The company raised $287.5 million through a secondary offering, which followed the suspension of an at-the-money equity offering [8]. - In a phase 3 trial, lorundrostat demonstrated a significant reduction in systolic pressure, outperforming a placebo [9]. - Following AstraZeneca's less favorable data for a competing product, Bank of America analyst Greg Harrison raised the target price for Mineralys to $43 per share, indicating a potential 24% gain [11]. - Despite the positive outlook, the company ended June with $325 million in cash, sufficient to last until 2027, raising concerns about the urgency of submitting for approval [12]. - Mineralys has a market cap of $2.7 billion, which could be affected by the timing of lorundrostat's approval compared to competitors [14]. Group 3: Market Potential - Precigen's market cap is approximately $1.3 billion, with expectations for Papzimeos potentially underestimated, as it is set to launch in a niche market without competition [15]. - Papzimeos could generate over $1 billion in annual sales at peak pricing, with a list price exceeding $200,000 per patient per year [16].

Core Insights - CytoMed Therapeutics Limited has successfully expanded clinical-scale natural killer (NK) cells from cord blood units that have been cryopreserved for over a decade, paving the way for new revenue streams and growth opportunities [1] - The company is reorganizing to create a new cord blood-derived biotech under LongevityBank Pte Ltd, which will focus on autologous therapies while CytoMed will concentrate on allogeneic therapies [2][3] - The acquisition of a licensed cord blood bank in Malaysia provides access to valuable cord blood for developing therapeutics for autoimmune diseases and cancers [4] Company Strategy - LongevityBank will leverage personalized cellular banking services for autologous therapies, while CytoMed will focus on donor blood-derived allogeneic therapies, which have ongoing clinical trials in Singapore and India [3] - The company plans to restart its cord blood banking business with new services, including immune cell banking, supported by resources from CytoMed [5] - Management intends to invest up to US$500,000 in LongevityBank to enhance laboratory capabilities and expedite research and development [5] Market Opportunity - The spinoff of LongevityBank is seen as a strategic move to manufacture cord blood-derived NK cells, which are being researched for their potential in treating autoimmune diseases [6] - The rising incidence of autoimmune diseases and increasing acceptance of personalized therapies present a favorable market environment for the company's offerings [7] - The cord blood bank acquisition is expected to positively impact the group's revenue, with better-than-anticipated performance [7]

As filed with the U.S. Securities and Exchange Commission on January 31, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant's name into English) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or Other Jurisdiction of Incorporation or Organization) Singapore 2834 Not Applicable (Primary S ...